Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Post by 99942Apophison Feb 18, 2022 5:04pm
606 Views
Post# 34443534

Upcoming patient data

Upcoming patient dataOur expectations of patient data in this upcoming Newsletter should contain results of patients 25 through to and include patient 30 for the period of 90 days.

Also we should receive data on patients 21, 22, 23 and 24  for their 180 period. This will give us a sense of future patients and their success going forward of which in my opinion will score very high.
Much talk lately whether we will hear any hint of other topics of interest as in partnership/partnerships, new patients,  Ph1 of GBM & NSCLC and any advancement in the therapeutic/vaccine story! With recent changes in personal at the company my opinion is we will have better communication in both positive and negative information. Have a good long weekend. 
<< Previous
Bullboard Posts
Next >>